Salient Bio

News

UK diagnostics firm Salient Bio has launched a robotics-driven COVID-19 mass testing platform after spinning out from Imperial College.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.